
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 446
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 446
Showing 1-25 of 446 citing articles:
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni, et al.
International Journal of Pharmaceutics (2021) Vol. 601, pp. 120586-120586
Open Access | Times Cited: 1001
Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni, et al.
International Journal of Pharmaceutics (2021) Vol. 601, pp. 120586-120586
Open Access | Times Cited: 1001
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939
The clinical progress of mRNA vaccines and immunotherapies
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 468
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 468
Chemistry of Lipid Nanoparticles for RNA Delivery
Yulia Eygeris, Mohit Gupta, Jeonghwan Kim, et al.
Accounts of Chemical Research (2021) Vol. 55, Iss. 1, pp. 2-12
Closed Access | Times Cited: 453
Yulia Eygeris, Mohit Gupta, Jeonghwan Kim, et al.
Accounts of Chemical Research (2021) Vol. 55, Iss. 1, pp. 2-12
Closed Access | Times Cited: 453
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 392
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 392
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103479-103479
Open Access | Times Cited: 379
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103479-103479
Open Access | Times Cited: 379
An ionizable lipid toolbox for RNA delivery
Xuexiang Han, Hanwen Zhang, Kamila Butowska, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 343
Xuexiang Han, Hanwen Zhang, Kamila Butowska, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 343
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Siri Tähtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 532-542
Open Access | Times Cited: 325
Siri Tähtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 532-542
Open Access | Times Cited: 325
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Chunfeng Li, Audrey Lee, Lilit Grigoryan, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 543-555
Open Access | Times Cited: 312
Chunfeng Li, Audrey Lee, Lilit Grigoryan, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 543-555
Open Access | Times Cited: 312
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 305
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 305
Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review
Reza Abbasi, Ghazal Shineh, Mohammadmahdi Mobaraki, et al.
Journal of Nanoparticle Research (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 286
Reza Abbasi, Ghazal Shineh, Mohammadmahdi Mobaraki, et al.
Journal of Nanoparticle Research (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 286
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 274
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 274
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Amit Khurana, Prince Allawadhi, Isha Khurana, et al.
Nano Today (2021) Vol. 38, pp. 101142-101142
Open Access | Times Cited: 220
Amit Khurana, Prince Allawadhi, Isha Khurana, et al.
Nano Today (2021) Vol. 38, pp. 101142-101142
Open Access | Times Cited: 220
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 214
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 214
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Barton F. Haynes, Kevin Wiehe, Persephone Borrow, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 142-158
Open Access | Times Cited: 211
Barton F. Haynes, Kevin Wiehe, Persephone Borrow, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 142-158
Open Access | Times Cited: 211
COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194
Principles for designing an optimal mRNA lipid nanoparticle vaccine
Edo Kon, Uri Elia, Dan Peer
Current Opinion in Biotechnology (2021) Vol. 73, pp. 329-336
Open Access | Times Cited: 181
Edo Kon, Uri Elia, Dan Peer
Current Opinion in Biotechnology (2021) Vol. 73, pp. 329-336
Open Access | Times Cited: 181
A Comprehensive Review of mRNA Vaccines
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2700-2700
Open Access | Times Cited: 180
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2700-2700
Open Access | Times Cited: 180
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 177
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 177
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Yuta Suzuki, Hiroshi Ishihara
Drug Metabolism and Pharmacokinetics (2021) Vol. 41, pp. 100424-100424
Open Access | Times Cited: 175
Yuta Suzuki, Hiroshi Ishihara
Drug Metabolism and Pharmacokinetics (2021) Vol. 41, pp. 100424-100424
Open Access | Times Cited: 175
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Pedro Morais, Hironori Adachi, Yi‐Tao Yu
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 175
Pedro Morais, Hironori Adachi, Yi‐Tao Yu
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 175
Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
Hiromi Muramatsu, Kieu Lam, Csaba Bajusz, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1941-1951
Open Access | Times Cited: 167
Hiromi Muramatsu, Kieu Lam, Csaba Bajusz, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1941-1951
Open Access | Times Cited: 167
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 161
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 161
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, et al.
Hepatology (2021) Vol. 74, Iss. 2, pp. 1049-1064
Open Access | Times Cited: 151
Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, et al.
Hepatology (2021) Vol. 74, Iss. 2, pp. 1049-1064
Open Access | Times Cited: 151